{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:01:01Z","timestamp":1790910061028,"version":"4.1.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T00:00:00Z","timestamp":1753056000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s10637-025-01565-0","type":"journal-article","created":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T16:36:27Z","timestamp":1753115787000},"page":"1013-1021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Low-dose PD-1 inhibition in relapsed\/refractory classic Hodgkin lymphoma: systematic review and meta-analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9646-690X","authenticated-orcid":false,"given":"Mobil","family":"Akhmedov","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pervin","family":"Zeynalova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Fedenko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Kaprin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,21]]},"reference":[{"key":"1565_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00561","volume":"8","author":"HO Alsaab","year":"2017","unstructured":"Alsaab HO, Sau S, Alzhrani R et al (2017) PD-1 and PD-L1 Checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol 8:561. https:\/\/doi.org\/10.3389\/fphar.2017.00561","journal-title":"Front Pharmacol"},{"issue":"31","key":"1565_CR2","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Ribrag V et al (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol 34(31):3733\u20133739. https:\/\/doi.org\/10.1200\/JCO.2016.67.3467","journal-title":"J Clin Oncol"},{"issue":"19","key":"1565_CR3","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","volume":"35","author":"R Chen","year":"2017","unstructured":"Chen R, Zinzani PL, Fanale MA et al (2017) Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma. J Clin Oncol 35(19):2125\u20132132. https:\/\/doi.org\/10.1200\/JCO.2016.72.1316","journal-title":"J Clin Oncol"},{"issue":"28","key":"1565_CR4","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.21.01056","volume":"39","author":"AJ Moskowitz","year":"2021","unstructured":"Moskowitz AJ, Shah G, Sch\u00f6der H et al (2021) Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma. J Clin Oncol 39(28):3109\u20133117. https:\/\/doi.org\/10.1200\/JCO.21.01056","journal-title":"J Clin Oncol"},{"issue":"Supplement_1","key":"1565_CR5","doi-asserted-by":"publisher","first-page":":4029","DOI":"10.1182\/blood-2019-123879","volume":"134","author":"LJ Bryan","year":"2019","unstructured":"Bryan LJ, Smith SE, Allen P et al (2019) Safety and toxicity profile of pembrolizumab (PEM) in combination with ICE chemotherapy followed by autologous stem cell transplantation for relapsed\/refractory classical Hodgkin lymphoma: no impairment in stem cell mobilization or engraftment. Blood 134(Supplement_1):4029. https:\/\/doi.org\/10.1182\/blood-2019-123879","journal-title":"Blood"},{"issue":"15","key":"1565_CR6","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","volume":"391","author":"AF Herrera","year":"2024","unstructured":"Herrera AF, LeBlanc M, Castellino SM et al (2024) Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma. N Engl J Med 391(15):1379\u20131389. https:\/\/doi.org\/10.1056\/NEJMoa2405888","journal-title":"N Engl J Med"},{"issue":"1","key":"1565_CR7","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/psp4.12133","volume":"6","author":"X Wang","year":"2017","unstructured":"Wang X, Feng Y, Bajaj G et al (2017) Quantitative characterization of the exposure-response relationship for cancer immunotherapy: a case study of nivolumab in patients with advanced melanoma. CPT Pharmacomet Syst Pharmacol 6(1):40\u201348. https:\/\/doi.org\/10.1002\/psp4.12133","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"issue":"10027","key":"1565_CR8","doi-asserted-by":"publisher","first-page":"1540","DOI":"10.1016\/S0140-6736(15)01281-7","volume":"387","author":"RS Herbst","year":"2016","unstructured":"Herbst RS, Baas P, Kim DW et al (2016) Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet 387(10027):1540\u20131550. https:\/\/doi.org\/10.1016\/S0140-6736(15)01281-7","journal-title":"Lancet"},{"issue":"2","key":"1565_CR9","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1002\/cpt.587","volume":"102","author":"M Stroh","year":"2017","unstructured":"Stroh M, Winter H, Marchand M et al (2017) Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther 102(2):305\u2013312. https:\/\/doi.org\/10.1002\/cpt.587","journal-title":"Clin Pharmacol Ther"},{"key":"1565_CR10","unstructured":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates | Journal of Clinical Oncology.  https:\/\/ascopubs.org\/doi\/full\/10.1200\/JCO.2009.26.7609. Accessed 11 Jan 2025"},{"issue":"1","key":"1565_CR11","doi-asserted-by":"publisher","first-page":"54","DOI":"10.4103\/CRST.CRST_29_19","volume":"2","author":"VM Patil","year":"2019","unstructured":"Patil VM, Noronha V, Joshi A et al (2019) Low doses in immunotherapy: are they effective? Cancer Res Statistics, and Treatment 2(1):54. https:\/\/doi.org\/10.4103\/CRST.CRST_29_19","journal-title":"Cancer Res Statistics, and Treatment"},{"issue":"5","key":"1565_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000480","volume":"4","author":"KV Lepik","year":"2020","unstructured":"Lepik KV, Fedorova LV, Kondakova EV et al (2020) A phase 2 study of nivolumab using a fixed dose of 40 mg (Nivo40) in patients with relapsed\/refractory Hodgkin lymphoma. Hemasphere 4(5):e480. https:\/\/doi.org\/10.1097\/HS9.0000000000000480","journal-title":"Hemasphere"},{"issue":"5","key":"1565_CR13","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1002\/hon.2787","volume":"38","author":"TSY Chan","year":"2020","unstructured":"Chan TSY, Hwang YY, Khong PL et al (2020) Low-dose pembrolizumab and nivolumab were efficacious and safe in relapsed and refractory classical Hodgkin lymphoma: experience in a resource-constrained setting. Hematol Oncol 38(5):726\u2013736. https:\/\/doi.org\/10.1002\/hon.2787","journal-title":"Hematol Oncol"},{"issue":"Suppl","key":"1565_CR14","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1097\/01.HS9.0000890816.89900.95","volume":"6","author":"L Fedorova","year":"2022","unstructured":"Fedorova L, Lepik K, Mikhailova N et al (2022) P062: the efficacy and safety of nivolumab 40 mg therapy versus 3 mg\/kg in patients with relapsed and refractory classic Hodgkin lymphoma. Hemasphere 6(Suppl):28\u201329. https:\/\/doi.org\/10.1097\/01.HS9.0000890816.89900.95","journal-title":"Hemasphere"},{"issue":"12","key":"1565_CR15","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1007\/s00277-024-06098-9","volume":"103","author":"PR Colunga-Pedraza","year":"2024","unstructured":"Colunga-Pedraza PR, Vaquera-Alfaro HA, Guzm\u00e1n-Mart\u00ednez Z et al (2024) Optimizing resources: low-dose nivolumab combinations in the management of relapsed\/refractory Hodgkin lymphoma. Ann Hematol 103(12):5607\u20135614. https:\/\/doi.org\/10.1007\/s00277-024-06098-9","journal-title":"Ann Hematol"},{"issue":"1","key":"1565_CR16","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1111\/bjh.13920","volume":"176","author":"YL Kwong","year":"2017","unstructured":"Kwong YL, Lopes D, Khong PL (2017) Low-dose pembrolizumab induced remission in patients with refractory classical Hodgkin lymphoma. Br J Haematol 176(1):131\u2013132. https:\/\/doi.org\/10.1111\/bjh.13920","journal-title":"Br J Haematol"},{"issue":"5","key":"1565_CR17","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1111\/bjh.15186","volume":"184","author":"A Minson","year":"2019","unstructured":"Minson A, Douglas G, Bilmon I, Grigg A (2019) Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD. Br J Haematol 184(5):840\u2013844. https:\/\/doi.org\/10.1111\/bjh.15186","journal-title":"Br J Haematol"},{"issue":"7","key":"1565_CR18","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1007\/s00277-017-3007-9","volume":"96","author":"YY Hwang","year":"2017","unstructured":"Hwang YY, Khong PL, Kwong YL (2017) Low-dose nivolumab induced remission in refractory classical Hodgkin lymphoma. Ann Hematol 96(7):1219\u20131220. https:\/\/doi.org\/10.1007\/s00277-017-3007-9","journal-title":"Ann Hematol"},{"issue":"1","key":"1565_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s12185-017-2181-9","volume":"106","author":"M Onizuka","year":"2017","unstructured":"Onizuka M, Kojima M, Matsui K et al (2017) Successful treatment with low-dose nivolumab in refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Int J Hematol 106(1):141\u2013145. https:\/\/doi.org\/10.1007\/s12185-017-2181-9","journal-title":"Int J Hematol"},{"key":"1565_CR20","unstructured":"4. Systematic reviews of effectiveness - JBI Manual for Evidence Synthesis - JBI Global Wiki.  https:\/\/jbi-global-wiki.refined.site\/space\/MANUAL\/355827955\/4.+Systematic+reviews+of+effectiveness. Accessed 10 Jan 2025"},{"issue":"5","key":"1565_CR21","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1097\/CJI.0000000000000411","volume":"45","author":"N Pathak","year":"2022","unstructured":"Pathak N, Pramanik R, Bakhshi S et al (2022) Modified protocol of nivolumab in relapsed\/refractory Hodgkin lymphoma: a brief communication of real world data. J Immunother 45(5):239. https:\/\/doi.org\/10.1097\/CJI.0000000000000411","journal-title":"J Immunother"},{"key":"1565_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.18620\/ctt-1866-8836-2018-7-2-28-35","volume":"7","author":"KV Lepik","year":"2018","unstructured":"Lepik KV, Kozlov AV, Borzenkova E et al (2018) Safety and efficacy of nivolumab applied at different dosage in the patients with relapsing Hodgkin lymphoma after allogeneic hematopoietic stem cell transplantation. Cell Ther Transplant 7:28\u201335","journal-title":"Cell Ther Transplant"},{"issue":"11","key":"1565_CR23","doi-asserted-by":"publisher","first-page":"13260","DOI":"10.18632\/oncotarget.7177","volume":"7","author":"JC Villasboas","year":"2016","unstructured":"Villasboas JC, Ansell SM, Witzig TE (2016) Targeting the PD-1 pathway in patients with relapsed classic Hodgkin lymphoma following allogeneic stem cell transplant is safe and effective. Oncotarget 7(11):13260\u201313264. https:\/\/doi.org\/10.18632\/oncotarget.7177","journal-title":"Oncotarget"},{"issue":"2","key":"1565_CR24","doi-asserted-by":"publisher","first-page":"85","DOI":"10.5045\/br.2020.2020014","volume":"55","author":"JY Hur","year":"2020","unstructured":"Hur JY, Yoon SE, Kim SJ, Kim WS (2020) Immune checkpoint inhibitors in patients with pretreated Hodgkin\u00cas lymphoma: a Korean single-center, retrospective study. Blood Research 55(2):85\u201390. https:\/\/doi.org\/10.5045\/br.2020.2020014","journal-title":"Blood Research"},{"issue":"4","key":"1565_CR25","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s00277-017-2931-z","volume":"96","author":"TS Chan","year":"2017","unstructured":"Chan TS, Luk TH, Lau JS, Khong PL, Kwong YL (2017) Low-dose pembrolizumab for relapsed\/refractory Hodgkin lymphoma: high efficacy with minimal toxicity. Ann Hematol 96(4):647\u2013651. https:\/\/doi.org\/10.1007\/s00277-017-2931-z","journal-title":"Ann Hematol"},{"key":"1565_CR26","unstructured":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano Classification | Journal of Clinical Oncology. https:\/\/ascopubs.org\/doi\/10.1200\/JCO.2013.54.8800. Accessed 26 June 2025"},{"issue":"21","key":"1565_CR27","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2016-05-718528","volume":"128","author":"BD Cheson","year":"2016","unstructured":"Cheson BD, Ansell S, Schwartz L et al (2016) Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy. Blood 128(21):2489\u20132496. https:\/\/doi.org\/10.1182\/blood-2016-05-718528","journal-title":"Blood"},{"issue":"8","key":"1565_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1080\/10428190903040048","volume":"50","author":"M Meignan","year":"2009","unstructured":"Meignan M, Gallamini A, Meignan M, Gallamini A, Haioun C (2009) Report on the First International Workshop on interim-PET scan in lymphoma. Leuk Lymphoma 50(8):1257\u20131260. https:\/\/doi.org\/10.1080\/10428190903040048","journal-title":"Leuk Lymphoma"},{"key":"1565_CR29","unstructured":"Nivolumab for relapsed\/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study | Blood Advances | American Society of Hematology. https:\/\/ashpublications.org\/bloodadvances\/article\/7\/20\/6266\/497222\/Nivolumab-for-relapsed-refractory-classical. Accessed 24 Jan 2025"},{"key":"1565_CR30","doi-asserted-by":"crossref","unstructured":"Five-year follow-up of KEYNOTE-087: pembrolizumab monotherapy for relapsed\/refractory classical Hodgkin lymphoma | Blood | American Society of Hematology. https:\/\/ashpublications.org\/blood\/article\/142\/10\/878\/496370\/Five-year-follow-up-of-KEYNOTE-087-pembrolizumab. Accessed 24 Jan 2025","DOI":"10.1182\/blood.2022019386"},{"issue":"18","key":"1565_CR31","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P et al (2017) Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood 129(18):2471\u20132478. https:\/\/doi.org\/10.1182\/blood-2016-11-749556","journal-title":"Blood"},{"key":"1565_CR32","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","volume":"4","author":"S Agrawal","year":"2016","unstructured":"Agrawal S, Feng Y, Roy A, Kollia G, Lestini B (2016) Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 4:72. https:\/\/doi.org\/10.1186\/s40425-016-0177-2","journal-title":"J Immunother Cancer"},{"key":"1565_CR33","doi-asserted-by":"crossref","unstructured":"Vega Mateos A (2024) Low-dose nivolumab plus AVD as front-line therapy for classical Hodgkin\u2019s lymphoma: preliminary results of a phase 2 trial. In: ASH.  https:\/\/ash.confex.com\/ash\/2024\/webprogram\/Paper208831.html. Accessed 24 Jan 2025","DOI":"10.1182\/blood-2024-208831"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-025-01565-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-025-01565-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:03:08Z","timestamp":1760194988000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-025-01565-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,21]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1565"],"URL":"https:\/\/doi.org\/10.1007\/s10637-025-01565-0","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,21]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interest"}}]}}